Stocktoria
Cytosorbents Corp CTSO
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2005-06-17
Cytosorbents Corp financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $37.1M | $35.6M | $31.1M | $34.7M | $43.2M |
| Gross profit | $26.5M | $24.9M | $22.0M | $20.7M | $32.1M |
| R&D expense | — | — | $15.7M | $15.1M | $16.4M |
| SG&A expense | $35.6M | $33.7M | $38.3M | $34.3M | $35.8M |
| Operating income | -$14.7M | -$16.5M | -$31.9M | -$31.5M | -$22.7M |
| Income tax | -$401,000 | -$1.7M | -$813,739 | -$1.1M | -$736,003 |
| Net income | -$8.2M | -$20.7M | -$29.2M | -$32.8M | -$24.6M |
| EPS (diluted) | $-0.13 | $-0.38 | $-0.65 | $-0.75 | $-0.57 |
| Operating cash flow | -$12.4M | -$14.4M | -$21.7M | -$28.2M | -$14.0M |
| Free cash flow | -$12.5M | -$14.7M | -$22.2M | -$34.3M | -$17.6M |
| Cash & equivalents | $6.2M | $3.3M | $14.1M | $22.1M | $52.1M |
| Inventory | $5.3M | $2.7M | $3.4M | $3.5M | $4.8M |
| Total assets | $44.2M | $47.4M | $53.0M | $63.2M | $89.5M |
| Total liabilities | $38.3M | $36.3M | $29.5M | $27.9M | $26.9M |
| Shareholders' equity | $5.9M | $11.1M | $23.5M | $35.4M | $62.6M |
Source: SEC EDGAR filings · CIK 0001175151 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.